Thrombopoietin (TPO), the ligand for c-mpl, stimulates prolieration of committed megakaryocytic progenitors and induces maturation of megakaryocytes. To better understand factors regulating TPO levels, we measured blood levels of TPO in patients with impaired platelet production due to aplastic anemia (AA) and with platelet destructive dmorders, including idiopathic thrombocytopenic purpura (ITPI, posttransfusion purpura (PTP), drug purpura (DP), and X-linked thrombocytopenia (XLTP). The TPO receptor capture enzyme immunoassay (EM) used had a detection limit of -150 to 200 pg/mL. TPO was undetectable in 88 of 89 normal individuals. Eighteen of 19 patients with AA and a mean platelet count (MPC) of 18,0001pL (2,000 to 61,0001pL) had markedly elevated TPO levels (mean, 1,467 pglml; range, 597 to 3,834 pglmL). Eight AA patients who responded to immunosuppressive therapy with their MPC HROMBOPOIETIN (TPO), also known as c-mpl ligand T or megakaryocyte growth and development factor (MGDF), has been isolated and cloned by several groups.'" It promotes proliferation of committed megakaryocytic precursors and differentiation of immature megakaryoblasts in vitro and in v~vo.'-~.~-' Expression of c-mpl in humans is restricted to nonlymphoid hematopoietic tissues including CD34+ cells, megakaryocytes, and platelets, with lower levels detected in endothelial cell^.^^'^ The predominant sites of TPO production are liver and, to a lesser degree, kidney, although the specific cell(s) responsible for production is not known.',2 Many lines of evidence indicate that TPO acting through c-mpl is essential for normal thrombopoiesis. For example, c-mpl antisense oligodeoxynucleotides inhibit synthesis of c-mpl mRNA in CD34+ cells and prevent them from forming megakaryocytic colonies.' In addition, both cmpl-deficient mice and homozygous TPO-deficient mice have markedly reduced megakaryocytes and circulating platelets.' '."
defined. Recent studies of experimental thrombocytopenia induced in animals by chemotherapy, radiation, or antiplatelet antibodies indicate an inverse relationship between circulating platelet mass and TPO level^.^."-'^ However, other observations, particularly in humans, indicate that megakaryocyte mass may be the principal regulator of TPO levels.16-" To understand this apparent inconsistency, we measured TPO by receptor capture enzyme immunoassay (EIA) in patients with equivalent degrees of thrombocytopenia due to two different mechanisms: decreased platelet production with megakaryocytic hypoplasia (AA) and increased platelet destruction with normal or increased megakaryocyte mass and documented or presumed normal platelet production (idiopathic thrombocytopenic purpura [ITF'], posttransfusion purpura [PTP] , drug purpura [DP] , and X-linked thrombocytopenia [XLTP] ).
MATERIALS AND METHODS

Patient selection.
Patients were referred to the Clinical Center for diagnosis andor treatment of thrombocytopenia or AA. Serum or plasma anticoagulated with EDTA or citrate was collected using a single syringe technique during periods of thrombocytopenia or after recovery and stored at -20°C. AA patients had moderate or severe disease by standard criteriaz2 and received immunosuppressive therapy with antithymocyte globulin (ATG) or ATG/ cyclosporine under NHLBI Institutional Review Board-approved research p r o t o~o l s .~~ ITP was diagnosed clinically as thrombocytopenia with normal or increased marrow megakaryocytes and no concurrent abnormality that could otherwise explain thrombocytopenia.
In all cases, diagnoses of PTP and DP were serologically confirmed.
Congenital microthrombocytopenia and eczema, with (Wiskott-Aldrich syndrome) or without immunodeficiency, were the bases for diagnosis of XLTP. '"In autologous platelet survivals were performed according to general guidelines," with the modification that apheresis rather than phlebotomy was performed to ensure ample red blood cell (RBC)-free platelets for labeling.
A full description of our TPO For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From hours with 100 ng/mL of a chimeric mpl-IgG.' Twofold dilutions of samples (starting at 15) and standards were added to wells and incubated for 1 hour. Bound TF'O was quantitated colorimetrically by addition of biotinylated affinity-purified polyclonal rabbit anti-TPO (Genentech, South San Francisco, CA) followed by streptavidin-conjugated peroxidase. Recombinant full-length TPO produced in mammalian cells was used to generate a curve that was subjected to a four-parameter nonlinear regression curve-fitting program. The working range of the assay, representing only data points on the linear portion, was 150 pg/mL to 10 ng/mL. The performance characteristics of the assay are similar in serum and plasma (independent of anticoagulant). TPO was below limits of detection in 88 of 89 normal individuals. The assay preferentially detects active full-length TPO yielding similar values to bioassays performed at Genentech. Table 1 provides clinical data and TPO levels on each patient studied. TPO levels in AA patients were threefold to 19-fold above the minimum detectable amount of 200 pg/ mL. Ten patients unresponsive to immunosuppressive therapy had a mean platelet count (Mpc) of 14,000/pL (2,000 to 34,OoO/pL) and a mean TPO level of 1,5 1 1 pg/mL (597 to 3,834 pg/mL). Eight patients who subsequently responded to immunosuppressive therapy had an initial MPC of 23,0001 pL (5,000 to 61,000/pL) and a mean TPO level of 1,517 pg/mL (710 to 2,880 pg/mL). After recovery, when their MPC was 134,00O/pL (92,000 to 175,000/pL), TPO levels were substantially decreased but still greater than controls (mean, 440 pg/mL; range, 193 to 771 pg/mL). Pretreatment bone marrow cellularity was severely depressed, with absent megakaryocytes in all but one AA patient. TPO was not detectable in 1 pancytopenic AA patient who had a platelet count of 19,000/pL and relative sparing of megakaryocytes on bone marrow biopsy. The patients responding to therapy had significant improvement in marrow cellularity, although megakaryocyte numbers, not quantitated precisely, appeared subnormal.
RESULTS
All 28 patients with acute and chronic thrombocytopenias resulting from platelet destruction had undetectable TPO levels. TPO levels in patients with ITP and those with aplastic anemia (before response to therapy) were significantly different (P < .0005) despite equivalent platelet counts (P = S4).
Of the 21 ITP patients, 14 had undergone splenectomies and none had ever received cytotoxic chemotherapy. Survival of autologous "%-labeled platelets in ITP patients no. 1, 3, 7, 13, 15, and 21 was decreased approximately proportionally to decreases in platelet levels, indicating that production was normal (data not shown). An allogeneic platelet survival on patient no. 1 with XLTP was 8 days and autologous survival approximately 2 days, consistent with the
DISCUSSION
Our data corroborate findings of others that TPO levels are characteristically high in humans and experimental animals with insufficient platelet production secondary to megakaryocytic hypoplasia. However, studies limited to those particular thrombocytopenias have not clearly distinguished whether elevated TPO levels correlate inversely with megakaryocyte or platelet mass. Our findings of undetectable TPO levels in a second group of patients with equal degrees of The mean duration of illness of ITP patients was 13.8 years (range, 1 month to 41 years); of PTP patients, 6 days (2 to 12 days); of DP patients, 4 days (1 to 7 days); and of XLTP patients, 8 years.
thrombocytopenia, but plentiful megakaryocytes and normal platelet production, help clarify this issue. Megakaryocyte mass, platelet turnover, or some parameter of megakaryocytic function, not circulating platelet number, appears to be the major regulator of TPO levels.
Before the isolation of TPO, bioassay measurements of For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From EMMONS ET AL serum megakaryocyte colony-stimulating activity (Meg-CSA) also correlated with megakaryocytic mas^.'^,'^ Patients with AA or amegakaryocytic thrombocytopenia had increased levels of Meg-CSA compared with normals, whereas a small number of patients with ITP did not. More recently, MGDF was elevated in 11 patients after myeloablative therapies and marrow or autologous peripheral stem cell transplants, at a time when marrow cellularity was likely suppressed, but before platelet counts decreased to less than lOO,OOO/pL. There is compelling evidence from animal experiments that platelet mass alone does not control TPO levels. Meg-CSA in plasma collected from sublethally irradiated rats was elevated even when platelets were transfused to maintain normal levels after irradiation." Additionally, mice lacking the p45 subunit of erythroid transcription factor NF-E2 have unelevated endogenous TPO levels despite absolute thrombocytopenia due to maturation arrest of megakaryocytes."
Studies of immunologically mediated thrombocytopenias have yielded some conflicting data between humans and rodents with respect to relationships between TPO levels and fluctuations in platelets or megakaryocytes. Acute thrombocytopenia induced by antiplatelet serum was associated with transitory markers of enhanced megakaryocytic stimulating activity in several early animal experiment^.^^-^'
More recently, specific increases in TPO were detected in mice and rabbits within 3 to 24 hours of precipitous decreases in platelets caused by antiplatelet era.','^,^' The duration of TPO elevations ranged from hours to several days. Comparable acute measurements on humans have not been reported. However, 2 of our patients with PTP and DP had undetectable TPO levels as early as days 1 and 2. If megakaryocyte mass or function is the major modulator of TPO in all species, one might postulate that hyperimmune antisera used experimentally injured megakaryoctytes. However, this is unlikely because the same antisera, administered repeatedly or in great excess to rodents did not maintain thrombo~ytopenia.'~ Rodents have more rapid platelet t~m o v e r~"~~ than humans and marked compensatory platelet production that precludes induction of experimental chronic immune thromb~cytopenia.'~ Humans are highly susceptible to antibody-induced thrombocytopenia and have limited compensatory platelet prod~ction.~'.~~ Perhaps regulation of TPO levels in rodents reflects responsiveness to factors not operable in humans.
Regardless of whether TPO expression is constitu-2.13, I9 or ind~cible?~ free TPO levels are regulated to some extent by receptor-mediated uptake. Platelets, whether transfused or incubated in vitro, lower plasma TPO through binding and possible metaboli~m.'~,~~ Larger platelets, often present in immune thrombocytopenias, may have increased receptor numbers that could account for greater uptake per platelet. However, platelet size would not explain low TPO levels in the XLTP patients who have microthrombocytes. Marrow CD34+ progenitors and megakaryocytes are also a part of the cellular pool bearing c-mpl, but may be less accessible to plasma TPO than circulating platelets. Perhaps transient TPO elevation can be caused by rapid diminution of the circulating platelet c-mpl pool, which is promptly corrected by continued platelet production at a normal rate. If so, increases of TPO in PTP, DP, or acute ITP may be elevated very early, during the period TP is developing, as in animal models, but not when it is established. Low TPO values with severe thrombocytopenia are not limited to immune-mediated disorders, for this association occurred in XLTP syndromes in which megakaryocyte mass is normal but congenitally defective platelets are prematurely destroyed.
TPO levels undetectable by our assay, yet slightly above normal, may have been missed. Nevertheless, there was essentially no overlap between the two groups of thrombocytopenic patients under study. Furthermore, there is no available data to suggest that putative inhibitors of the TPO EIA, including anti-c-mpl, anti-TPO, microparticulate, or soluble c-mpl, would have explained the uniformly low TPO levels in patients with destructive thrombocytopenias.
TPO measurements may be helpful to differentiate decreased platelet production from increased peripheral destruction in rare instances of thrombocytopenia with borderline marrow hypoplasia. Our single AA patient with residual megakaryocytes and a low TPO level may have had peripheral destruction contributing to his thrombocytopenia. There are reports suggesting that a minority of ITP patients have low rather than characteristic normal or increased platelet p r o d~c t i o n .~~ Measurement of TPO levels may help determine whether this subset of ITP patients truly exists.
Our observations raise the possibility that exogenous TPO might speed recovery from acute immune thrombocytopenias and elevate platelet counts in those patients with chronic ITP in whom the rate of platelet destruction can be overcome by physiologically attainable increases in production.
